Alzheimer's biotech comes un­der at­tack as pe­ti­tion calls for tri­al halt, da­ta au­dit — and it's fight­ing back

Lit­tle Cas­sa­va Sci­ences has com­plete faith in its ex­per­i­men­tal Alzheimer’s drug. Ever since piv­ot­ing away from a four-time re­ject anal­gesic (and from its for­mer iden­ti­ty as Pain Ther­a­peu­tics), the biotech has plowed steadi­ly away at clin­i­cal tri­als for a new lead pro­gram called simu­fil­am, plot­ting ma­jor Phase III tri­als and sig­nif­i­cant in­vest­ment in­to the neu­rode­gen­er­a­tive dis­ease — even be­fore the FDA ap­proval of Bio­gen’s Aduhelm rein­vig­o­rat­ed the en­tire field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER